SAN FRANCISCO, Feb. 21, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the

- Upsized Initial Public Offering raises $97.6 million in gross proceeds - - BIO89-100 continues to advance in Phase 1b/2a NASH study - SAN FRANCISCO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and

SAN FRANCISCO and HERZLIYA, Israel, Nov. 13, 2019 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the closing

SAN FRANCISCO and HERZLIYA, Israel, Nov. 11, 2019 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company, announced that two posters related to its investigational therapy, BIO89-100, will be presented today at The Liver Meeting 2019, the annual meeting of the

SAN FRANCISCO and HERZLIYA, Israel, Nov. 11, 2019 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the pricing

-New Patent Provides Coverage through 2038- SAN FRANCISCO and HERZLIYA, Israel, Sept. 25, 2019 /PRNewswire/ -- 89bio, Inc. (89bio or the company), a clinical-stage biopharmaceutical company, has initiated dosing in its proof of concept Phase 1b/2a clinical trial evaluating its product candidate,

- Company Strengthens Leadership Team with Three Executive Hires: CFO, CTO, and VP of Biometrics and Development Strategy - SAN FRANCISCO, and HERZLIYA, Israel, Aug. 8, 2019 /PRNewswire/ -- 89Bio Ltd. (89bio), a clinical-stage biopharmaceutical company, today announced that the first patients have

- BIO89-100 was generally safe and well tolerated at all dose levels - - Robust and durable pharmacodynamic effects observed across key lipid parameters - SAN FRANCISCO and HERZLIYA, Israel, May 22, 2019 /PRNewswire/ -- 89bio LTD, a clinical-stage biopharmaceutical company focused on nonalcoholic

Data presented in Late-Breaking Presentation at the EASL International Liver Congress™ SAN FRANCISCO and HERZLIYA, Israel, April 11, 2019 /PRNewswire/ -- 89bio LTD, a clinical-stage biopharmaceutical company focused on nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders,

SAN FRANCISCO and HERZLIYA, Israel, March 28, 2019 /PRNewswire/ -- 89bio LTD, a clinical-stage biopharmaceutical company focused on nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders, today announced that preclinical data regarding BIO89-100, a novel long-acting